
Quarterly report 2025-Q3
added 11-13-2025
BioNano Genomics Financial Statements 2011-2025 | BNGO
Annual Financial Statements BioNano Genomics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
3.55 M | 683 K | 37 M | 614 M | 1.47 B | 37.4 M | 40.8 M | - | - | - | - | - | - | - |
Shares |
1.27 M | 569 K | 28.9 M | 277 M | 133 M | 34.3 M | 10.1 M | - | - | - | - | - | - | - |
Historical Prices |
2.79 | 1.2 | 1.28 | 2.22 | 11.1 | 1.03 | 4.1 | - | - | - | - | - | - | - |
Net Income |
-112 M | -232 M | -133 M | -72.4 M | -41.1 M | -29.8 M | -18.5 M | -23.4 M | -18.8 M | - | - | - | - | - |
Revenue |
30.8 M | 36.1 M | 27.8 M | 18 M | 8.5 M | 10.1 M | 12 M | 9.51 M | 6.79 M | - | - | - | - | - |
Cost of Revenue |
30.4 M | 26.6 M | 21.9 M | 14.1 M | 5.73 M | 6.77 M | 8.71 M | 6.03 M | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | 2.77 M | 3.36 M | 3.29 M | 3.47 M | 3.21 M | - | - | - | - | - |
Operating Income |
-104 M | -215 M | -132 M | -77.1 M | -38.6 M | -25.9 M | -20.4 M | -23.2 M | - | - | - | - | - | - |
Interest Expense |
-10.1 M | -20.5 M | 298 K | 927 K | 2.52 M | 2.29 M | 1.38 M | 591 K | - | - | - | - | - | - |
EBITDA |
-90 M | -202 M | -122 M | -73.8 M | -37.1 M | -24.7 M | -19.1 M | -21.1 M | -20.1 M | - | - | - | - | - |
Operating Expenses |
- | - | - | - | 41.3 M | 29.2 M | 23.7 M | 26.1 M | 24.4 M | - | - | - | - | - |
General and Administrative Expenses |
51.9 M | 92.8 M | 88.6 M | 58.5 M | 31.1 M | 20.2 M | 14.2 M | 14.1 M | 13 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement BioNano Genomics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
5.34 M | 3.44 M | 2.69 M | 1.87 M | 1.43 M | 1.13 M | 879 K | 45.8 M | 35 M | 31.5 M | 30.2 M | 29.7 M | 29 M | 28.6 M | 285 M | 290 M | 280 M | 279 M | 264 M | 190 M | 133 M | 90.9 M | 35.6 M | 34.3 M | 10.9 M | 10.9 M | 10.2 M | 10.1 M | 7.78 M | 3.36 M | 3.32 M | 77.3 K | 2.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-8.5 M | -6.86 M | -3.1 M | - | -44.2 M | -16.2 M | -31.4 M | - | -113 M | -38.9 M | -37.1 M | - | -31.8 M | -32.2 M | -30 M | - | -20.8 M | -18.8 M | -9.95 M | - | -10.8 M | -8.07 M | -10.5 M | -7.9 M | -6.4 M | -6.4 M | -7.9 M | -6.41 M | -4.93 M | -3.31 M | -3.85 M | 5.92 M | -23.4 M | 6.67 M | 5.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
7.37 M | 6.73 M | 6.46 M | - | 6.07 M | 7.77 M | 8.77 M | - | 9.32 M | 8.66 M | 7.42 M | - | 7.22 M | 6.67 M | 5.7 M | - | 4.66 M | 3.86 M | 3.17 M | - | 2.2 M | 1.18 M | 1.14 M | 2.79 M | 3.31 M | 2.18 M | 1.85 M | 4.01 M | 2.83 M | 3.39 M | 1.77 M | 2.85 M | 2.74 M | 2.2 M | 1.72 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
4 M | 3.26 M | 3.52 M | - | 14.5 M | 5.19 M | 5.94 M | - | 6.57 M | 6.35 M | 5.34 M | - | 5.41 M | 5.2 M | 4.84 M | - | 3.5 M | 2.42 M | 2.12 M | - | 1.46 M | 603 K | 856 K | 1.69 M | 2.38 M | 1.56 M | 1.15 M | 2.99 M | 3.07 M | 1.81 M | 841 K | 1.5 M | 1.69 M | 1.64 M | 1.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-8.54 M | -7.8 M | -8.46 M | - | -43.9 M | -17 M | -31.1 M | - | -113 M | -39.2 M | -37.8 M | - | -32.1 M | -32.1 M | -29.9 M | - | -20.7 M | -16.5 M | -11.2 M | - | -10.2 M | -7.44 M | -9.76 M | - | -5.68 M | -6.84 M | -6.18 M | - | -5.97 M | -4.01 M | -4.34 M | - | -5.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-219 K | 676 K | 5.08 M | - | -697 K | 363 K | -1.36 M | - | -45 K | -330 K | 76 K | - | 73 K | 74 K | 77 K | - | 2 K | 210 K | 603 K | - | 589 K | 561 K | 761 K | - | 578 K | 645 K | 273 K | - | 404 K | 408 K | 302 K | - | 145 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | -6.03 M | - | - | - | -28.1 M | - | - | - | -34.7 M | - | -25.3 M | -32.1 M | -27.7 M | - | -19.2 M | -16.5 M | -10.7 M | - | -9.32 M | -6.84 M | -9.47 M | - | -5.41 M | -6.58 M | -5.92 M | - | -5.58 M | -3.63 M | -3.94 M | - | -4.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
9.06 M | 8.35 M | 9.03 M | - | 9.46 M | 11.6 M | 19.1 M | - | 24.9 M | 26.9 M | 26 M | - | 21.2 M | 21.8 M | 20.3 M | - | 15.3 M | 13.8 M | 9.53 M | - | 8.66 M | 5.61 M | 7.37 M | - | 4.45 M | 5.06 M | 4.79 M | - | 3.22 M | 3.49 M | 2.9 M | - | 3.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Main types of financial statements BioNano Genomics BNGOFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting BioNano Genomics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
$ 64.79 | 2.0 % | $ 25 B | ||
|
Brainsway Ltd.
BWAY
|
$ 17.23 | 1.5 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 21.15 | 11.37 % | $ 233 M | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
$ 101.24 | 0.04 % | $ 18.8 B | ||
|
Biomerica
BMRA
|
$ 2.31 | 2.01 % | $ 5.31 M | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
$ 0.36 | -0.39 % | $ 10.6 M | ||
|
Guardant Health
GH
|
$ 104.81 | -0.39 % | $ 12.9 B | ||
|
Celcuity
CELC
|
$ 98.24 | -0.25 % | $ 3.88 B | ||
|
DarioHealth Corp.
DRIO
|
$ 11.75 | -0.47 % | $ 333 M | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
$ 185.09 | 2.99 % | $ 15.3 B | ||
|
IDEXX Laboratories
IDXX
|
$ 733.11 | 0.57 % | $ 60.5 B | ||
|
Danaher Corporation
DHR
|
$ 228.08 | 1.74 % | $ 167 B | ||
|
Illumina
ILMN
|
$ 128.88 | 0.12 % | $ 20.5 B | ||
|
Anixa Biosciences
ANIX
|
$ 4.25 | -3.41 % | $ 136 K | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 267.33 | -0.14 % | $ 22.4 B | ||
|
Lantheus Holdings
LNTH
|
$ 58.6 | -0.81 % | $ 4.06 B | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Medpace Holdings
MEDP
|
$ 589.45 | 0.25 % | $ 18.2 B | ||
|
Mettler-Toledo International
MTD
|
$ 1 457.09 | -0.75 % | $ 30.9 B | ||
|
Myriad Genetics
MYGN
|
$ 7.06 | -0.03 % | $ 640 M | ||
|
ENDRA Life Sciences
NDRA
|
$ 5.81 | -1.43 % | $ 3.12 M | ||
|
NeoGenomics
NEO
|
$ 12.02 | -0.04 % | $ 1.52 B | ||
|
Neogen Corporation
NEOG
|
$ 5.91 | -0.25 % | $ 1.28 B | ||
|
Biodesix
BDSX
|
$ 7.79 | - | $ 1.01 B | ||
|
National Research Corporation
NRC
|
$ 16.27 | -3.1 % | $ 399 M | ||
|
Natera
NTRA
|
$ 237.72 | 1.48 % | $ 23.4 B | ||
|
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | ||
|
Castle Biosciences
CSTL
|
$ 39.24 | 0.31 % | $ 1.09 B | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 184.06 | 0.16 % | $ 20.4 B | ||
|
Fulgent Genetics
FLGT
|
$ 28.38 | -0.49 % | $ 858 M | ||
|
Organovo Holdings
ONVO
|
- | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
- | -16.95 % | $ 1.54 M | ||
|
Pacific Biosciences of California
PACB
|
$ 2.33 | 4.69 % | $ 591 M | ||
|
PerkinElmer
PKI
|
- | -0.91 % | $ 14.7 B | ||
|
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
$ 24.56 | 8.81 % | $ 31.9 M | ||
|
Personalis
PSNL
|
$ 10.09 | 4.18 % | $ 598 M | ||
|
RadNet
RDNT
|
$ 79.11 | -1.13 % | $ 5.78 B | ||
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M |